112 related articles for article (PubMed ID: 34969970)
1. Engineering CAR-T cells to activate small-molecule drugs in situ.
Gardner TJ; Lee JP; Bourne CM; Wijewarnasuriya D; Kinarivala N; Kurtz KG; Corless BC; Dacek MM; Chang AY; Mo G; Nguyen KM; Brentjens RJ; Tan DS; Scheinberg DA
Nat Chem Biol; 2022 Feb; 18(2):216-225. PubMed ID: 34969970
[TBL] [Abstract][Full Text] [Related]
2. SEAKER cells coordinate cellular immunotherapy with localized chemotherapy.
Lane IC; Jan M
Trends Pharmacol Sci; 2022 Oct; 43(10):804-805. PubMed ID: 35491262
[TBL] [Abstract][Full Text] [Related]
3. CAR T Cells Activate Cancer Therapy.
Cancer Discov; 2022 Mar; 12(3):592. PubMed ID: 35086924
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies.
Aranda-Orgilles B; Chion-Sotinel I; Skinner J; Grudman S; Mumford B; Dixon C; Postigo Fernandez J; Erler P; Duchateau P; Gouble A; Galetto R; Poirot L
Cancer Immunol Res; 2023 Jul; 11(7):946-961. PubMed ID: 37257169
[TBL] [Abstract][Full Text] [Related]
5. Host-cell Interactions of Engineered T cell Micropharmacies.
Bourne CM; Wallisch P; Dacek M; Gardner T; Pierre S; Vogt K; Corless BC; Bah MA; Romero Pichardo J; Charles A; Kurtz KG; Tan DS; Scheinberg DA
bioRxiv; 2023 May; ():. PubMed ID: 37205431
[TBL] [Abstract][Full Text] [Related]
6. Nanomodified Switch Induced Precise and Moderate Activation of CAR-T Cells for Solid Tumors.
Wang X; Meng F; Li X; Xue L; Chen A; Qiu Y; Zhang Z; Li L; Liu F; Li Y; Sun Z; Chu Y; Xu R; Yu L; Shao J; Tian M; Qian X; Liu Q; Liu B; Li R
Adv Sci (Weinh); 2023 Apr; 10(12):e2205044. PubMed ID: 36755195
[TBL] [Abstract][Full Text] [Related]
7. Novel Drug Delivery Systems: An Important Direction for Drug Innovation Research and Development.
Chen Q; Yang Z; Liu H; Man J; Oladejo AO; Ibrahim S; Wang S; Hao B
Pharmaceutics; 2024 May; 16(5):. PubMed ID: 38794336
[TBL] [Abstract][Full Text] [Related]
8. Programmable synthetic receptors: the next-generation of cell and gene therapies.
Teng F; Cui T; Zhou L; Gao Q; Zhou Q; Li W
Signal Transduct Target Ther; 2024 Jan; 9(1):7. PubMed ID: 38167329
[TBL] [Abstract][Full Text] [Related]
9. Rationally designed approaches to augment CAR-T therapy for solid tumor treatment.
Zhu C; Wu Q; Sheng T; Shi J; Shen X; Yu J; Du Y; Sun J; Liang T; He K; Ding Y; Li H; Gu Z; Wang W
Bioact Mater; 2024 Mar; 33():377-395. PubMed ID: 38059121
[TBL] [Abstract][Full Text] [Related]
10. Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications.
Kurtz K; Eibler L; Dacek MM; Carter LM; Veach DR; Lovibond S; Reynaud E; Qureshy S; McDevitt MR; Bourne C; Monette S; Punzalan B; Khayat S; Verma S; Kesner AL; Cheung NV; Schöder H; Gajecki L; Cheal SM; Larson SM; Scheinberg DA; Krebs S
Theranostics; 2023; 13(15):5469-5482. PubMed ID: 37908719
[No Abstract] [Full Text] [Related]
11. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies.
Ruella M; Korell F; Porazzi P; Maus MV
Nat Rev Drug Discov; 2023 Dec; 22(12):976-995. PubMed ID: 37907724
[TBL] [Abstract][Full Text] [Related]
12. Probiotic-guided CAR-T cells for solid tumor targeting.
Vincent RL; Gurbatri CR; Li F; Vardoshvili A; Coker C; Im J; Ballister ER; Rouanne M; Savage T; de Los Santos-Alexis K; Redenti A; Brockmann L; Komaranchath M; Arpaia N; Danino T
Science; 2023 Oct; 382(6667):211-218. PubMed ID: 37824640
[TBL] [Abstract][Full Text] [Related]
13. Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development.
Tang L; Pan S; Wei X; Xu X; Wei Q
Mol Ther; 2023 Nov; 31(11):3146-3162. PubMed ID: 37803832
[TBL] [Abstract][Full Text] [Related]
14. Development of a
Lee JP; Corless BC; Gardner TJ; Scheinberg DA; Tan DS
Org Lett; 2023 Sep; 25(34):6295-6299. PubMed ID: 37602700
[TBL] [Abstract][Full Text] [Related]
15. Challenges and solutions for therapeutic TCR-based agents.
Malviya M; Aretz ZEH; Molvi Z; Lee J; Pierre S; Wallisch P; Dao T; Scheinberg DA
Immunol Rev; 2023 Nov; 320(1):58-82. PubMed ID: 37455333
[TBL] [Abstract][Full Text] [Related]
16. Catalyst-free thiazolidine formation chemistry enables the facile construction of peptide/protein-cell conjugates (PCCs) at physiological pH.
Liu X; Wang Y; Ye B; Bi X
Chem Sci; 2023 Jul; 14(26):7334-7345. PubMed ID: 37416697
[TBL] [Abstract][Full Text] [Related]
17. CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process.
Altvater B; Kailayangiri S; Spurny C; Flügge M; Meltzer J; Greune L; Urban K; Schwöppe C; Brand C; Schliemann C; Hintelmann H; Harrach S; Hartmann W; Abken H; Kuehle J; Schambach A; Görlich D; Berdel WE; Rossig C
Cancer Gene Ther; 2023 Oct; 30(10):1355-1368. PubMed ID: 37391502
[TBL] [Abstract][Full Text] [Related]
18. Host Interactions with Engineered T-cell Micropharmacies.
Bourne CM; Wallisch P; Dacek MM; Gardner TJ; Pierre S; Vogt K; Corless BC; Bah MA; Romero-Pichardo JE; Charles A; Kurtz KG; Tan DS; Scheinberg DA
Cancer Immunol Res; 2023 Sep; 11(9):1253-1265. PubMed ID: 37379366
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
